Biogen Inc (BIIB)

274.04
+1.93(+0.71%)
After Hours
272.50
-1.54(-0.56%)
- Real-time Data
  • Volume:
    936,142
  • Bid/Ask:
    271.04/277.00
  • Day's Range:
    270.66 - 279.20

BIIB Overview

Prev. Close
272.11
Day's Range
270.66 - 279.2
Revenue
12.6B
Open
270.66
52 wk Range
223.25 - 363.92
EPS
19.06
Volume
936,142
Market Cap
41.26B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
1,103,107
P/E Ratio
14.27
Beta
0.43
1-Year Change
-12.73%
Shares Outstanding
150,554,750
Next Earnings Date
Jul 27, 2021
What is your sentiment on Biogen Inc?
or
Market is currently closed. Voting is open during market hours.

Biogen Inc News

Biogen Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyStrong BuyNeutral
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuySell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyNeutral

Biogen Inc Company Profile

Biogen Inc Company Profile

Employees
9100

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Read More
  • will be massive return for the next decade
    0
    • good fundamentals im in for long run
      1
      • Why are we going down?
        0
        • a lot of good news ahead , just hold and be patient. 300+ price target
          1
          • https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
            0
            • Next week? Maybe
              0
              • FDA desicion posponed, Market wont like it
                2
                • buy Koss for next week
                  1
                  • i did 2 days ago... was a mess... any tip for today? I need to be back after such disaster....
                    1
                • 400
                  0
                  • Fishy I Agree
                    0
                    • Price action very fishy
                      1
                      • tomorrow go up buy
                        2
                        • it will fall further
                          4
                          • why? the earning are outstanding
                            1
                          • You want to buy more, than I understand. Otherwise you are really **** up!
                            1
                        • Buy now sell at 350 in 6 months
                          2
                          • less than 6 month, before april
                            0
                        • Sell at 350
                          1
                          • BUY AND BUY AGAIN
                            1
                            • If keeps revenue growth at 0 for next years and stock price increases with 50% still cheap!!!
                              1
                              • I just took 10 shares...we are in 7 year low
                                1
                                • i will buy it again at 215
                                  3
                                  • good chance to buy nowagree?
                                    1
                                    • Don't Bottom fishing, Below 220 Coming up
                                      3
                                      • we are in 7 year low, are you sure?
                                        0
                                      • CONFIRM...DON'T BUY - LONG TERM BELOW 180 COMING.
                                        3
                                      • Don't agree. The stock will slowly go up towards March 21 expecting FDA approval. If FDA don't approve then, it will take a dive again
                                        1
                                    • Don't Bottom fishing, Below 220 Coming up
                                      2
                                      • time to buy again?
                                        1
                                        • i sold thursday with huge profit. i will buy ½50 in deep, i bought  alibaba with another ½50
                                          1
                                          • Time to sell
                                            0
                                            • if you can:)
                                              0
                                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.